---
title: "Jefferies Sticks to Their Buy Rating for Kailera Therapeutics, Inc. (KLRA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287949963.md"
description: "Jefferies analyst Roger Song has maintained a Buy rating for Kailera Therapeutics, Inc. (KLRA) with a price target of $48.00. The analyst consensus suggests a Strong Buy rating for the company, with an average price target of $39.00. Song has a 40.86% success rate on his stock recommendations."
datetime: "2026-05-28T15:55:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287949963.md)
  - [en](https://longbridge.com/en/news/287949963.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287949963.md)
---

# Jefferies Sticks to Their Buy Rating for Kailera Therapeutics, Inc. (KLRA)

Jefferies analyst Roger Song maintained a Buy rating on Kailera Therapeutics, Inc. today and set a price target of $48.00.

### Memorial Day Sale – Claim 70% Off TipRanks

-   Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
-   Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter

Song covers the Healthcare sector, focusing on stocks such as United Therapeutics, Oruka Therapeutics, and Fate Therapeutics. According to TipRanks, Song has an average return of 0.5% and a 40.86% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kailera Therapeutics, Inc. with a $39.00 average price target.

### Related Stocks

- [KLRA.US](https://longbridge.com/en/quote/KLRA.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)
- [UTHR.US](https://longbridge.com/en/quote/UTHR.US.md)
- [ORKA.US](https://longbridge.com/en/quote/ORKA.US.md)
- [FATE.US](https://longbridge.com/en/quote/FATE.US.md)

## Related News & Research

- [TD Cowen Reaffirms Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)](https://longbridge.com/en/news/287719655.md)
- [Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates | KLRA Stock News](https://longbridge.com/en/news/287673757.md)
- [Mizuho Securities Sticks to Their Buy Rating for Palvella Therapeutics (PVLA)](https://longbridge.com/en/news/287808371.md)
- [Jefferies Reaffirms Their Buy Rating on Entero Healthcare Solutions Limited (ENTERO)](https://longbridge.com/en/news/287919829.md)
- [Jefferies Just Upgraded Generac Stock. Here’s Why.](https://longbridge.com/en/news/287674477.md)